secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001493152-26-011922
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa Therapeutics receives Nasdaq delisting bid-price notice; ineligible for cure due to prior reverse split
--------------------------------------------------------------------------------

- Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
- Company not eligible for standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) due to reverse stock split within past year.
- Intends to request hearing before Nasdaq Hearing Panel; request stays suspension/delisting pending panel decision and possible 180-day extension.
- No assurance that panel will grant extension or that securities (ERNA, ERNAW) will remain listed on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-011922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer